目次

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY
1.1. Market Overview
1.2. Key Findings
1.3. Market Segmentation
1.4. Competitive Landscape
1.5. Challenges and Opportunities
1.6. Future Outlook

2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the study
2.2.1. Research Objective
2.2.2. Assumption
2.2.3. Limitations

3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation

4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities

5. MARKET FACTOR ANALYSIS
5.1. Value chain Analysis
5.2. Porter's Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis

6. CD19 THERAPEUTICS MARKET, BY TYPE OF THERAPY (USD BILLION)
6.1. Monoclonal Antibodies
6.2. CAR T-cell Therapy
6.3. Small Molecule Inhibitors
6.4. Bispecific Antibodies

7. CD19 THERAPEUTICS MARKET, BY INDICATION (USD BILLION)
7.1. Non-Hodgkin Lymphoma
7.2. Acute Lymphoblastic Leukemia
7.3. Chronic Lymphocytic Leukemia

8. CD19 THERAPEUTICS MARKET, BY ADMINISTRATION ROUTE (USD BILLION)
8.1. Intravenous
8.2. Subcutaneous
8.3. Intramuscular

9. CD19 THERAPEUTICS MARKET, BY END USER (USD BILLION)
9.1. Hospitals
9.2. Clinics
9.3. Research Institutions

10. CD19 THERAPEUTICS MARKET, BY REGIONAL (USD BILLION)
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. UK
10.2.3. France
10.2.4. Russia
10.2.5. Italy
10.2.6. Spain
10.2.7. Rest of Europe
10.3. APAC
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Malaysia
10.3.6. Thailand
10.3.7. Indonesia
10.3.8. Rest of APAC
10.4. South America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Argentina
10.4.4. Rest of South America
10.5. MEA
10.5.1. GCC Countries
10.5.2. South Africa
10.5.3. Rest of MEA

11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market share Analysis
11.4. Major Growth Strategy in the CD19 Therapeutics Market
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the CD19 Therapeutics Market
11.7. Key developments and growth strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales and Operating Income
11.8.2. Major Players R&D Expenditure. 2023

12. COMPANY PROFILES
12.1. Sanofi
12.1.1. Financial Overview
12.1.2. Products Offered
12.1.3. Key Developments
12.1.4. SWOT Analysis
12.1.5. Key Strategies
12.2. Johnson and Johnson
12.2.1. Financial Overview
12.2.2. Products Offered
12.2.3. Key Developments
12.2.4. SWOT Analysis
12.2.5. Key Strategies
12.3. Kite Pharma
12.3.1. Financial Overview
12.3.2. Products Offered
12.3.3. Key Developments
12.3.4. SWOT Analysis
12.3.5. Key Strategies
12.4. Gilead Sciences
12.4.1. Financial Overview
12.4.2. Products Offered
12.4.3. Key Developments
12.4.4. SWOT Analysis
12.4.5. Key Strategies
12.5. Novartis
12.5.1. Financial Overview
12.5.2. Products Offered
12.5.3. Key Developments
12.5.4. SWOT Analysis
12.5.5. Key Strategies
12.6. AstraZeneca
12.6.1. Financial Overview
12.6.2. Products Offered
12.6.3. Key Developments
12.6.4. SWOT Analysis
12.6.5. Key Strategies
12.7. Amgen
12.7.1. Financial Overview
12.7.2. Products Offered
12.7.3. Key Developments
12.7.4. SWOT Analysis
12.7.5. Key Strategies
12.8. AbbVie
12.8.1. Financial Overview
12.8.2. Products Offered
12.8.3. Key Developments
12.8.4. SWOT Analysis
12.8.5. Key Strategies
12.9. BristolMyers Squibb
12.9.1. Financial Overview
12.9.2. Products Offered
12.9.3. Key Developments
12.9.4. SWOT Analysis
12.9.5. Key Strategies
12.10. Takeda Pharmaceutical
12.10.1. Financial Overview
12.10.2. Products Offered
12.10.3. Key Developments
12.10.4. SWOT Analysis
12.10.5. Key Strategies
12.11. bluebird bio
12.11.1. Financial Overview
12.11.2. Products Offered
12.11.3. Key Developments
12.11.4. SWOT Analysis
12.11.5. Key Strategies
12.12. Celgene
12.12.1. Financial Overview
12.12.2. Products Offered
12.12.3. Key Developments
12.12.4. SWOT Analysis
12.12.5. Key Strategies
12.13. Roche
12.13.1. Financial Overview
12.13.2. Products Offered
12.13.3. Key Developments
12.13.4. SWOT Analysis
12.13.5. Key Strategies
12.14. Merck and Co.
12.14.1. Financial Overview
12.14.2. Products Offered
12.14.3. Key Developments
12.14.4. SWOT Analysis
12.14.5. Key Strategies
12.15. Regeneron Pharmaceuticals
12.15.1. Financial Overview
12.15.2. Products Offered
12.15.3. Key Developments
12.15.4. SWOT Analysis
12.15.5. Key Strategies

13. APPENDIX
13.1. References
13.2. Related Reports

LIST OF TABLES
TABLE 1. LIST OF ASSUMPTIONS
TABLE 2. NORTH AMERICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 3. NORTH AMERICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 4. NORTH AMERICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 5. NORTH AMERICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 6. NORTH AMERICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 7. US CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 8. US CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 9. US CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 10. US CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 11. US CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 12. CANADA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 13. CANADA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 14. CANADA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 15. CANADA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 16. CANADA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 17. EUROPE CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 18. EUROPE CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 19. EUROPE CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 20. EUROPE CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 21. EUROPE CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 22. GERMANY CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 23. GERMANY CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 24. GERMANY CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 25. GERMANY CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 26. GERMANY CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 27. UK CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 28. UK CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 29. UK CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 30. UK CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 31. UK CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 32. FRANCE CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 33. FRANCE CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 34. FRANCE CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 35. FRANCE CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 36. FRANCE CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 37. RUSSIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 38. RUSSIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 39. RUSSIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 40. RUSSIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 41. RUSSIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 42. ITALY CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 43. ITALY CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 44. ITALY CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 45. ITALY CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 46. ITALY CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 47. SPAIN CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 48. SPAIN CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 49. SPAIN CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 50. SPAIN CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 51. SPAIN CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 52. REST OF EUROPE CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 53. REST OF EUROPE CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 54. REST OF EUROPE CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 55. REST OF EUROPE CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 56. REST OF EUROPE CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 57. APAC CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 58. APAC CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 59. APAC CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 60. APAC CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 61. APAC CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 62. CHINA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 63. CHINA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 64. CHINA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 65. CHINA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 66. CHINA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 67. INDIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 68. INDIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 69. INDIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 70. INDIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 71. INDIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 72. JAPAN CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 73. JAPAN CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 74. JAPAN CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 75. JAPAN CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 76. JAPAN CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 77. SOUTH KOREA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 78. SOUTH KOREA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 79. SOUTH KOREA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 80. SOUTH KOREA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 81. SOUTH KOREA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 82. MALAYSIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 83. MALAYSIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 84. MALAYSIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 85. MALAYSIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 86. MALAYSIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 87. THAILAND CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 88. THAILAND CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 89. THAILAND CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 90. THAILAND CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 91. THAILAND CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 92. INDONESIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 93. INDONESIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 94. INDONESIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 95. INDONESIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 96. INDONESIA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 97. REST OF APAC CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 98. REST OF APAC CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 99. REST OF APAC CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 100. REST OF APAC CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 101. REST OF APAC CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 102. SOUTH AMERICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 103. SOUTH AMERICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 104. SOUTH AMERICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 105. SOUTH AMERICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 106. SOUTH AMERICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 107. BRAZIL CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 108. BRAZIL CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 109. BRAZIL CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 110. BRAZIL CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 111. BRAZIL CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 112. MEXICO CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 113. MEXICO CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 114. MEXICO CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 115. MEXICO CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 116. MEXICO CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 117. ARGENTINA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 118. ARGENTINA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 119. ARGENTINA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 120. ARGENTINA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 121. ARGENTINA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 122. REST OF SOUTH AMERICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 123. REST OF SOUTH AMERICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 124. REST OF SOUTH AMERICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 125. REST OF SOUTH AMERICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 126. REST OF SOUTH AMERICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 127. MEA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 128. MEA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 129. MEA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 130. MEA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 131. MEA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 132. GCC COUNTRIES CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 133. GCC COUNTRIES CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 134. GCC COUNTRIES CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 135. GCC COUNTRIES CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 136. GCC COUNTRIES CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 137. SOUTH AFRICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 138. SOUTH AFRICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 139. SOUTH AFRICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 140. SOUTH AFRICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 141. SOUTH AFRICA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 142. REST OF MEA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY TYPE OF THERAPY, 2019-2032 (USD BILLIONS)
TABLE 143. REST OF MEA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 144. REST OF MEA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 145. REST OF MEA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 146. REST OF MEA CD19 THERAPEUTICS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 147. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
TABLE 148. ACQUISITION/PARTNERSHIP

LIST OF FIGURES
FIGURE 1. MARKET SYNOPSIS
FIGURE 2. NORTH AMERICA CD19 THERAPEUTICS MARKET ANALYSIS
FIGURE 3. US CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 4. US CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 5. US CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 6. US CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 7. US CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 8. CANADA CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 9. CANADA CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 10. CANADA CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 11. CANADA CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 12. CANADA CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 13. EUROPE CD19 THERAPEUTICS MARKET ANALYSIS
FIGURE 14. GERMANY CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 15. GERMANY CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 16. GERMANY CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 17. GERMANY CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 18. GERMANY CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 19. UK CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 20. UK CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 21. UK CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 22. UK CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 23. UK CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 24. FRANCE CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 25. FRANCE CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 26. FRANCE CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 27. FRANCE CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 28. FRANCE CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 29. RUSSIA CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 30. RUSSIA CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 31. RUSSIA CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 32. RUSSIA CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 33. RUSSIA CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 34. ITALY CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 35. ITALY CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 36. ITALY CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 37. ITALY CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 38. ITALY CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 39. SPAIN CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 40. SPAIN CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 41. SPAIN CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 42. SPAIN CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 43. SPAIN CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 44. REST OF EUROPE CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 45. REST OF EUROPE CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 46. REST OF EUROPE CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 47. REST OF EUROPE CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 48. REST OF EUROPE CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 49. APAC CD19 THERAPEUTICS MARKET ANALYSIS
FIGURE 50. CHINA CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 51. CHINA CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 52. CHINA CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 53. CHINA CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 54. CHINA CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 55. INDIA CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 56. INDIA CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 57. INDIA CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 58. INDIA CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 59. INDIA CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 60. JAPAN CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 61. JAPAN CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 62. JAPAN CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 63. JAPAN CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 64. JAPAN CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 65. SOUTH KOREA CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 66. SOUTH KOREA CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 67. SOUTH KOREA CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 68. SOUTH KOREA CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 69. SOUTH KOREA CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 70. MALAYSIA CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 71. MALAYSIA CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 72. MALAYSIA CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 73. MALAYSIA CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 74. MALAYSIA CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 75. THAILAND CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 76. THAILAND CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 77. THAILAND CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 78. THAILAND CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 79. THAILAND CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 80. INDONESIA CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 81. INDONESIA CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 82. INDONESIA CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 83. INDONESIA CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 84. INDONESIA CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 85. REST OF APAC CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 86. REST OF APAC CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 87. REST OF APAC CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 88. REST OF APAC CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 89. REST OF APAC CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 90. SOUTH AMERICA CD19 THERAPEUTICS MARKET ANALYSIS
FIGURE 91. BRAZIL CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 92. BRAZIL CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 93. BRAZIL CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 94. BRAZIL CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 95. BRAZIL CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 96. MEXICO CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 97. MEXICO CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 98. MEXICO CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 99. MEXICO CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 100. MEXICO CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 101. ARGENTINA CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 102. ARGENTINA CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 103. ARGENTINA CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 104. ARGENTINA CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 105. ARGENTINA CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 106. REST OF SOUTH AMERICA CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 107. REST OF SOUTH AMERICA CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 108. REST OF SOUTH AMERICA CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 109. REST OF SOUTH AMERICA CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 110. REST OF SOUTH AMERICA CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 111. MEA CD19 THERAPEUTICS MARKET ANALYSIS
FIGURE 112. GCC COUNTRIES CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 113. GCC COUNTRIES CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 114. GCC COUNTRIES CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 115. GCC COUNTRIES CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 116. GCC COUNTRIES CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 117. SOUTH AFRICA CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 118. SOUTH AFRICA CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 119. SOUTH AFRICA CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 120. SOUTH AFRICA CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 121. SOUTH AFRICA CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 122. REST OF MEA CD19 THERAPEUTICS MARKET ANALYSIS BY TYPE OF THERAPY
FIGURE 123. REST OF MEA CD19 THERAPEUTICS MARKET ANALYSIS BY INDICATION
FIGURE 124. REST OF MEA CD19 THERAPEUTICS MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 125. REST OF MEA CD19 THERAPEUTICS MARKET ANALYSIS BY END USER
FIGURE 126. REST OF MEA CD19 THERAPEUTICS MARKET ANALYSIS BY REGIONAL
FIGURE 127. KEY BUYING CRITERIA OF CD19 THERAPEUTICS MARKET
FIGURE 128. RESEARCH PROCESS OF MRFR
FIGURE 129. DRO ANALYSIS OF CD19 THERAPEUTICS MARKET
FIGURE 130. DRIVERS IMPACT ANALYSIS: CD19 THERAPEUTICS MARKET
FIGURE 131. RESTRAINTS IMPACT ANALYSIS: CD19 THERAPEUTICS MARKET
FIGURE 132. SUPPLY / VALUE CHAIN: CD19 THERAPEUTICS MARKET
FIGURE 133. CD19 THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2024 (% SHARE)
FIGURE 134. CD19 THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019 TO 2032 (USD Billions)
FIGURE 135. CD19 THERAPEUTICS MARKET, BY INDICATION, 2024 (% SHARE)
FIGURE 136. CD19 THERAPEUTICS MARKET, BY INDICATION, 2019 TO 2032 (USD Billions)
FIGURE 137. CD19 THERAPEUTICS MARKET, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
FIGURE 138. CD19 THERAPEUTICS MARKET, BY ADMINISTRATION ROUTE, 2019 TO 2032 (USD Billions)
FIGURE 139. CD19 THERAPEUTICS MARKET, BY END USER, 2024 (% SHARE)
FIGURE 140. CD19 THERAPEUTICS MARKET, BY END USER, 2019 TO 2032 (USD Billions)
FIGURE 141. CD19 THERAPEUTICS MARKET, BY REGIONAL, 2024 (% SHARE)
FIGURE 142. CD19 THERAPEUTICS MARKET, BY REGIONAL, 2019 TO 2032 (USD Billions)
FIGURE 143. BENCHMARKING OF MAJOR COMPETITORS